These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 3574114)

  • 21. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
    Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Limits and possibilities of cytostatic therapy with massive doses of cyclophosphamide].
    Chiarelli G; Garutti GP; Rambaldi P
    Arcisp S Anna Ferrara; 1967; 20(3):385-400. PubMed ID: 5606860
    [No Abstract]   [Full Text] [Related]  

  • 23. [A clinical trial of a new method for treating chronic nephritis with superhigh doses of cyclophosphane].
    Shilov EM; Krasnova TM; Ivanov AA; Tareeva IE
    Klin Med (Mosk); 1995; 73(3):86-90. PubMed ID: 8577125
    [No Abstract]   [Full Text] [Related]  

  • 24. [Massive cytostatic therapy after orthovoltage therapy].
    Schawow A
    Radiobiol Radiother (Berl); 1970; 11(6):655-9. PubMed ID: 5509232
    [No Abstract]   [Full Text] [Related]  

  • 25. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
    Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
    J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
    Kennedy MJ; Zahurak ML; Donehower RC; Noe D; Grochow LB; Sartorius S; Chen TL; Bowling K; Duerr M; Rowinsky EK
    Clin Cancer Res; 1998 Feb; 4(2):349-56. PubMed ID: 9516922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment with large doses of Endoxan].
    Araujo E; Estevez R; Sanchez Suarez R; Chacon R; Gonzalez G
    Med Monatsschr; 1967 Aug; 21(8):371-3. PubMed ID: 5597100
    [No Abstract]   [Full Text] [Related]  

  • 30. [First clinical experiences with ultrahigh single doses of cyclophosphamide].
    Schmitz G; Gross R
    Med Welt; 1967 Apr; 16():985-9. PubMed ID: 5585096
    [No Abstract]   [Full Text] [Related]  

  • 31. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
    Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
    Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy of non-Hodgkin lymphoma by the COP schedule].
    Krajewska B; Solska E; Dziewulska-Bokiniec A
    Wiad Lek; 1981 May; 34(10):815-9. PubMed ID: 7293181
    [No Abstract]   [Full Text] [Related]  

  • 33. EST 0469B--comparison of high- and low-dose cyclophosphamide in human lung cancer.
    Hall TC; Pocock S; Brodovsky H; Horton J; Shnider BI; Colsky J; Oberfield RA
    Med Pediatr Oncol; 1978; 5(1):231-40. PubMed ID: 370535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
    Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical trial with fractionated high doses of cyclophosphamide].
    Macchiavelli M; Leone BA; Romero A; Rabinovich MG; Pérez JE
    Medicina (B Aires); 1986; 46(4):475-6. PubMed ID: 3574114
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.
    Ershler WB; Hacker MP; Newman RA; Stewart JA; Gamelli RL; Krakoff IH
    Cancer Treat Rep; 1983 Dec; 67(12):1145-7. PubMed ID: 6652633
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.